JP2016512693A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512693A5
JP2016512693A5 JP2016503010A JP2016503010A JP2016512693A5 JP 2016512693 A5 JP2016512693 A5 JP 2016512693A5 JP 2016503010 A JP2016503010 A JP 2016503010A JP 2016503010 A JP2016503010 A JP 2016503010A JP 2016512693 A5 JP2016512693 A5 JP 2016512693A5
Authority
JP
Japan
Prior art keywords
reagent
providing
cell
tissue sample
chaotrope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503010A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512693A (ja
JP6465857B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/029198 external-priority patent/WO2014144682A1/en
Publication of JP2016512693A publication Critical patent/JP2016512693A/ja
Publication of JP2016512693A5 publication Critical patent/JP2016512693A5/ja
Application granted granted Critical
Publication of JP6465857B2 publication Critical patent/JP6465857B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503010A 2013-03-15 2014-03-14 外科的に摘出された組織における癌細胞の生存能を維持するための方法および試薬 Active JP6465857B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361798627P 2013-03-15 2013-03-15
US61/798,627 2013-03-15
PCT/US2014/029198 WO2014144682A1 (en) 2013-03-15 2014-03-14 Methods and reagents for maintaining the viability of cancer cells in surgically removed tissue

Publications (3)

Publication Number Publication Date
JP2016512693A JP2016512693A (ja) 2016-05-09
JP2016512693A5 true JP2016512693A5 (https=) 2017-04-13
JP6465857B2 JP6465857B2 (ja) 2019-02-06

Family

ID=51528685

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503010A Active JP6465857B2 (ja) 2013-03-15 2014-03-14 外科的に摘出された組織における癌細胞の生存能を維持するための方法および試薬

Country Status (17)

Country Link
US (5) US9113623B2 (https=)
EP (2) EP2970878B1 (https=)
JP (1) JP6465857B2 (https=)
CN (2) CN112806352A (https=)
CA (1) CA2941929C (https=)
CY (1) CY1120801T1 (https=)
DK (1) DK2970878T3 (https=)
ES (1) ES2684582T3 (https=)
HR (1) HRP20181352T1 (https=)
HU (1) HUE039933T2 (https=)
LT (1) LT2970878T (https=)
PL (1) PL2970878T3 (https=)
PT (1) PT2970878T (https=)
RS (1) RS57900B1 (https=)
SI (1) SI2970878T1 (https=)
SM (1) SMT201800457T1 (https=)
WO (1) WO2014144682A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2970878T (lt) 2013-03-15 2018-11-12 Truckee Applied Genomics, Llc Vėžio ląstelių chirurginiu būdu pašalintame audinyje gyvybingumo palaikymo būdai ir reagenatai
US10053676B2 (en) 2014-11-25 2018-08-21 Bio-Rad Laboratories, Inc. Arginine improves polymerase storage stability
CN107333750A (zh) * 2017-06-11 2017-11-10 成都吱吖科技有限公司 一种长时血液细胞稳定剂
WO2021055170A1 (en) * 2019-09-17 2021-03-25 Longhorn Vaccines And Diagnostics, Llc Multipurpose compositions for collecting and transporting biological material
WO2022010916A1 (en) * 2020-07-07 2022-01-13 Truckee Applied Genomics, Llc Cell preservation reagents and methods of use
CN117063915B (zh) * 2023-08-17 2026-02-24 镜像绮点(上海)细胞技术有限公司 原代肿瘤细胞冻存液

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409826A (en) * 1993-06-08 1995-04-25 Coulter Corporation Preserved, non-infectious control cells prepared by the modulation or modification of normal cells
CA2250570A1 (en) * 1996-03-26 1997-10-02 Eli Lilly And Company Formulations of ob protein
US20010007673A1 (en) 1999-11-12 2001-07-12 Merrill Seymour Goldenberg Sustained-release delayed gels
US7569342B2 (en) 1997-12-10 2009-08-04 Sierra Molecular Corp. Removal of molecular assay interferences
US20080064108A1 (en) 1997-12-10 2008-03-13 Tony Baker Urine Preservation System
WO1999029904A2 (en) 1997-12-10 1999-06-17 Sierra Diagnostics, Inc. Methods and reagents for preservation of dna in bodily fluids
AU1848602A (en) * 2000-12-04 2002-06-18 Lymphotec Inc. Cell-preservation liquid and method of preserving cells by using the liquid
KR20020066778A (ko) 2001-02-13 2002-08-21 한국과학기술연구원 체내 난흡수 물질의 흡수촉진용 조성물과 제형 및 그의제조방법
WO2008111981A1 (en) 2007-03-14 2008-09-18 Sierra Molecular Corporation Compositions, systems, and methods for preservation of macromolecules
WO2004052184A2 (en) * 2002-12-12 2004-06-24 Oncotech, Inc. Genes related to sensitivity and resistance to chemotherapeutic drug treatment
US8793895B2 (en) * 2006-02-10 2014-08-05 Praxair Technology, Inc. Lyophilization system and method
US8652782B2 (en) * 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8080645B2 (en) * 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
WO2008033936A2 (en) 2006-09-12 2008-03-20 Sierra Molecular Corporation Removal of molecular assay interferences for nucleic acids employing buffered solutions of chaotropes
WO2008052170A2 (en) 2006-10-27 2008-05-02 Sierra Molecular Corporation Penetratable septum cap
WO2008071384A1 (en) 2006-12-13 2008-06-19 Roche Diagnostics Gmbh Use of tde for the isolation of nucleic acids
KR20100015578A (ko) 2007-03-14 2010-02-12 시에라 몰레큘러 코포레이션 세포 및/또는 거대분자의 보존 및/또는 안정화를 위한 조성물, 시스템 및 방법
EP2217244A4 (en) * 2007-11-12 2011-08-31 Bipar Sciences Inc TREATMENT OF NUTRITIONAL CANCER AND EGG CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTITUMOROUS MEDICINES
US20100003748A1 (en) 2008-07-03 2010-01-07 Tony Baker Compositions, systems, and methods for stabilization of a cell and/or macromolecule
WO2010028156A2 (en) 2008-09-04 2010-03-11 Board Of Regents, The University Of Texas System Dual modality detection of apoptosis
US9133343B2 (en) * 2009-11-30 2015-09-15 Enzo Biochem, Inc. Dyes and compositions, and processes for using same in analysis of protein aggregation and other applications
CN102318597B (zh) * 2011-08-19 2013-04-03 张雪云 一种液基细胞保存液组合物及其制备方法
LT2970878T (lt) 2013-03-15 2018-11-12 Truckee Applied Genomics, Llc Vėžio ląstelių chirurginiu būdu pašalintame audinyje gyvybingumo palaikymo būdai ir reagenatai

Similar Documents

Publication Publication Date Title
JP2016512693A5 (https=)
PL3313991T3 (pl) Modyfikowany czynnik ix oraz kompozycje, sposoby i zastosowania do transferu genów do komórek, narządów i tkanek
BR112015017405A2 (pt) composições que incluem agentes hidrofobizantes e estabilizantes e métodos para preparação e utilização das mesmas
EP3310931A4 (en) CRISPR / CAS9 COMPLEX FOR INTRODUCING A FUNCTIONAL POLYPEPTIDE IN CELLS OF A BLOOD CELL LINE
HRP20260181T1 (hr) Priprema i skladištenje lipozomskih rnk formulacija koje su pogodne za terapiju
JP2016520647A5 (https=)
CL2016003324A1 (es) Construcciones de anticuerpos multiespecificos.
EP3564356A4 (en) SOLUTION FOR CRYOPRESERVATION, CRYOGENIZATION PRODUCT, AND METHOD FOR CRYOPRESERVATION OF ANIMAL CELLS OR ANIMAL TISSUES
BR112015021189A2 (pt) métodos de banco de células de alta densidade
JP2015061520A5 (https=)
NZ739339A (en) Apoptosis signal-regulating kinase inhibitor
PT2958913T (pt) Agonistas de recetores de esfingosina-1-fosfato, métodos para a sua preparação e composições farmacêuticas que os contêm como agente ativo
EA201691629A1 (ru) Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
IL280962A (en) Methods for delivering gene editing reagents to cells within organs
WO2015153772A3 (en) Zirconium-89 oxine complex as a cell labeling agent for positron emission tomography
EP3202885A4 (en) Novel biological activity testing structure for tracking single cell, using gelling agents
EP3202409A4 (en) Composition, cell construct, islet transplant kit, islet cell transplant therapeutic agent and blood sugar reducing agent, composition including islets, kit including islets, and islet transplant therapeutic agent and blood sugar reducing agent
DK3079675T3 (da) Farmaceutisk sammensætning indeholdende nikotinsyre og/eller nikotinamid til anvendelse til gavnlig påvirkning af blodlipidniveauer ved modificering af tarmmikrobiataen
DK3232780T3 (da) Vandige adjuvans-sammensætninger, der indeholder elektrolyt, sammensætninger, som indeholder et aktivt stof, og anvendelse deraf
MX2013006188A (es) Agentes de generacion de imagenes pet de apoptosis.
MX389168B (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
BR112013021784A2 (pt) composição de reagente, e, método para a recuperação de um metal de uma solução aquosa
BR112017026666A2 (pt) armazenagem de longo prazo e conservação de plaquetas
EP3727585C0 (en) SYSTEM FOR INDUCING SONOPERMEABILIZATION TRANSFER OF A DRUG INTO CANCER CELLS